IL18BP and hemophagocytic syndrome: An ongoing multicenter, double-blind, placebo-controlled, randomized withdrawal trial evaluates efficacy and safety of IL-18BP (tadekinig alfa) in pediatric patients with NLRC4 associated hyperinflammation including HLH or XIAP deficiency, diseases, in which IL-18 levels are particularly elevated (73).